| Literature DB >> 27956614 |
Seung-Min Park1,2, Dawson J Wong3, Chin Chun Ooi4, David M Kurtz2,5,6, Ophir Vermesh1,2, Amin Aalipour1,2, Susie Suh7, Kelsey L Pian8, Jacob J Chabon9, Sang Hun Lee10, Mehran Jamali1, Carmen Say11, Justin N Carter11, Luke P Lee10, Ware G Kuschner12,13, Erich J Schwartz14, Joseph B Shrager15, Joel W Neal6,16, Heather A Wakelee6,16, Maximilian Diehn9,11,16,17, Viswam S Nair18,13,17, Shan X Wang19,8,17, Sanjiv S Gambhir18,2,17.
Abstract
Circulating tumor cells (CTCs) are established cancer biomarkers for the "liquid biopsy" of tumors. Molecular analysis of single CTCs, which recapitulate primary and metastatic tumor biology, remains challenging because current platforms have limited throughput, are expensive, and are not easily translatable to the clinic. Here, we report a massively parallel, multigene-profiling nanoplatform to compartmentalize and analyze hundreds of single CTCs. After high-efficiency magnetic collection of CTC from blood, a single-cell nanowell array performs CTC mutation profiling using modular gene panels. Using this approach, we demonstrated multigene expression profiling of individual CTCs from non-small-cell lung cancer (NSCLC) patients with remarkable sensitivity. Thus, we report a high-throughput, multiplexed strategy for single-cell mutation profiling of individual lung cancer CTCs toward minimally invasive cancer therapy prediction and disease monitoring.Entities:
Keywords: circulating tumor cells; microfluidics; rare-cell sorting; reverse transcription-PCR; single-cell analysis
Mesh：
Substances：
Year: 2016 PMID： 27956614 PMCID： PMC5206556 DOI： 10.1073/pnas.1608461113
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205